Premium
Therapeutic Effect and Side Effects of Danazol in Endometriosis
Author(s) -
Nagata Yukihiro,
Nakamura Genichi,
Kusuda Masahiko
Publication year - 1982
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1982.tb00570.x
Subject(s) - danazol , medicine , endometriosis , discontinuation , pregnancy rate , regimen , ovulation , pregnancy , therapeutic effect , gastroenterology , infertility , side effect (computer science) , surgery , gynecology , hormone , biology , genetics , computer science , programming language
Danazol was administered to patients with endometriosis and infertility in a study designed to assess its therapeutic efficacy and side effects. Forty‐six patients with endometriosis were treated with 300 mg or 400 mg/day of danazol for a mean duration of 22 weeks. Although the symptomatic improvement rate was greater than 90%, the improvement in cul‐de‐sac nodularity was 47% and endometriomas did not regress during danazol therapy. The pregnancy rate and recurrence rate following this drug regimen were 44% and 28%, respectively. These rates were similar to those obtained in a comparable group of patients treated with a pseudopregnancy regimen. Mild hepatocellular damage was observed in 43% of patients taking 400 mg/day of danazol, necessitating discontinuation of medication in some instances. On reducing the dosage to 300 mg/day, however, the incidence of hepatocellular damage was lowered to almost the same level as with treatment with pseudo‐pregnancy therapy. After completion of danazol therapy ovulation returned quickly in all instances, hepatocellular damage disappeared and serum levels of GOT and GPT were rapidly restored to normal.